Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by NBW Capital LLC

NBW Capital LLC lowered its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 27.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 19,430 shares of the company’s stock after selling 7,500 shares during the quarter. NBW Capital LLC’s holdings in Spyre Therapeutics were worth $452,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of SYRE. Quest Partners LLC boosted its position in Spyre Therapeutics by 271.2% during the third quarter. Quest Partners LLC now owns 5,654 shares of the company’s stock worth $166,000 after acquiring an additional 4,131 shares during the last quarter. Intech Investment Management LLC purchased a new position in Spyre Therapeutics during the third quarter worth approximately $246,000. Charles Schwab Investment Management Inc. raised its stake in Spyre Therapeutics by 239.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 333,275 shares of the company’s stock worth $9,802,000 after purchasing an additional 235,094 shares during the period. The Manufacturers Life Insurance Company raised its stake in Spyre Therapeutics by 15.0% during the third quarter. The Manufacturers Life Insurance Company now owns 43,460 shares of the company’s stock worth $1,278,000 after purchasing an additional 5,678 shares during the period. Finally, FMR LLC raised its stake in Spyre Therapeutics by 1.5% during the third quarter. FMR LLC now owns 7,623,881 shares of the company’s stock worth $224,218,000 after purchasing an additional 115,898 shares during the period. Institutional investors and hedge funds own 80.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Robert W. Baird increased their price target on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. The Goldman Sachs Group raised shares of Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 18th. Finally, Wedbush reaffirmed an “outperform” rating and set a $65.00 price target on shares of Spyre Therapeutics in a research note on Monday, January 13th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $54.83.

Spyre Therapeutics Trading Down 8.9 %

Shares of SYRE stock opened at $17.94 on Tuesday. The company’s fifty day simple moving average is $22.25 and its 200-day simple moving average is $26.76. Spyre Therapeutics, Inc. has a 52 week low of $17.56 and a 52 week high of $47.97. The company has a market cap of $922.67 million, a PE ratio of -2.40 and a beta of 2.85.

Spyre Therapeutics (NASDAQ:SYRE) last issued its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.08. Equities research analysts expect that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).